| Literature DB >> 24992184 |
Haojun Xie1, Yuanxiong Cheng1, Yating Huo1, Guohua Huang1, Jin Su1.
Abstract
BACKGROUND: Evidence is increasingly accumulated about multiple roles for the β2-adrenoceptor gene in asthma. The results were inconsistent partly due to small sample sizes. To assess the association between β2-adrenoceptor gene polymorphisms and asthma risk, a meta-analysis was performed.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24992184 PMCID: PMC4081822 DOI: 10.1371/journal.pone.0101861
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow Diagram for Inclusion of Studies in Meta-analysis.
The initial search identified 2205 articles, of which, 37 were included in the final analysis.
Characteristics of studies included in meta-analysis.
| First author[Ref] | Year | Country | Ethnicity | Case (n) | Control (n) | Study design | Age group | GenotypingMethod |
| Abdul Vahab Saadi# | 2013 | India | Asian | 150 | 150 | Case-control | Mixed | Sequencing |
| Al-Rubaish A# | 2011 | Saudi Arabia | Arabia | 73 | 85 | Case-control | Children | PCR-RFLP |
| Barr RG# | 2001 | USA | Caucasian | 171 | 137 | Case-control | Adults | Allele specific |
| Bhatnagar, P # | 2005 | India | Asian | 101 | 55 | Case-control | Adults | Sequencing |
| Binaei S# | 2003 | USA | Caucasian | 38 | 155 | Case-control | Children | PCR-RFLP |
| Birbian N# | 2012 | India | Asian | 410 | 414 | Case-control | Adults | PCR-RFLP |
| Chan IH# | 2008 | China | Asian | 295 | 173 | Case-control | Children | PCR-RFLP |
| ChiangCH# | 2012 | China | Asian | 476 | 115 | Case-control | Adults | PCR-RFLP |
| Dewar JC# | 1998 | UK | Caucasian | 117 | 511 | Cross-section | Adults | Allele specific |
| Gao G# | 2000 | China | Asian | 58 | 89 | Case-control | Adults | PCR-RFLP |
| Gao JM# | 2002 | China | Asian | 125 | 96 | Case-control | Adults | PCR-RFLP |
| Hakonarson H# | 2001 | Iceland | Caucasian | 324 | 199 | Case-control | Adults | Sequencing |
| Holloway JW# | 2000 | New Zealand | Caucasian | 154 | 91 | Case-control | Adults | Sequencing |
| Hopes E# | 1998 | UK | Caucasian | 102 | 317 | Cross-section | Children | Allele specific |
| Isaza C# | 2012 | Colombia | NA | 109 | 137 | Case-control | Children | Sequencing |
| Karam RA# | 2013 | Egypt | African | 90 | 110 | Case-control | Children | Allele specific |
| Kohyama K# | 2011 | Japan | Asian | 300 | 100 | Case-control | Adults | Sequencing |
| Kotani Y# | 1999 | Japan | Asian | 117 | 103 | Case-control | Adults | Allele specific |
| Leung TF# | 2002 | China | Asian | 76 | 70 | Case-control | Children | PCR-RFLP |
| Li H# | 2009 | China | Asian | 192 | 192 | Children | PCR-RFLP | |
| Lin YC# | 2003 | China | Asian | 80 | 69 | Case-control | Children | Allele specific |
| Martinez FD# | 1997 | USA | Caucasian | 38 | 229 | Cross-section | Children | PCR-RFLP |
| Matheson MC# | 2006 | Australia | Caucasian | 123 | 221 | Case-control | Adults | ARMS |
| Munakata M# | 2006 | Japan | Asian | 46 | 100 | Case-control | NA | Sequencing |
| Pino-Yanes M# | 2013 | Spain | Hispanic | 596 | 1240 | Case-control | Children | iPLEXH Gold assay |
| Potter PC# | 1993 | South Africa | African | 22 | 30 | Case-control | Children | PCR-RFLP |
| Qiu YY# | 2010 | China | Asian | 201 | 276 | Case-control | Adults | Sequencing |
| Reihsaus E# | 1993 | USA | NA | 51 | 56 | Case-control | Adults | Sequencing |
| Santillan AA# | 2003 | Mexico | NA | 303 | 604 | Case-control | Adults | PCR-RFLP |
| Shachor J# | 2003 | Israel | Arabia | 66 | 113 | Case-control | Adults | PCR-RFLP |
| Szczepankiewicz A# | 2009 | Poland | Caucasian | 113 | 121 | Case-control | Children | PCR-RFLP |
| Tatarskyy, P.F # | 2011 | Ukraine | Caucasian | 114 | 86 | Case-control | Children | Multiplexed PCR |
| Thomsen M# | 2012 | Denmark | Caucasian | 547 | 8386 | Cross-section | Adults | PCR-RFLP |
| Wang JY# | 2009 | China | Asian | 442 | 545 | Case-control | Children | Taq Man |
| Wang Z# | 2001 | China | Asian | 128 | 136 | Case-control | Adults | Allele specific |
| Ye, Y.M# | 2010 | Korea | Asian | 102 | 322 | Case-control | Adults | Sequencing |
| Zheng, B.Q# | 2012 | China | Asian | 198 | 110 | Case-control | Children | Sequencing |
NA, not available; PCR, polymerase chain reaction; RFLP, restricted fragment length polymorphisms; SSP, sequence.
-specific primers; SPT, skin prick test; BHR,bronchial hyperresponsiveness; TDI, toluene diisocyanate; ARMS, amplification refractory mutation system;Mixed, participants involved children and adults.
Results of the pooled analyses and subgroup analyses for the β2AR Arg/Gly16 polymorphism and asthma risk.
| Variable | n | Case/Control | Arg16 vs Gly16 | Arg16Arg vs Gly16Gly | Arg16Arg vs Gly16Gly/ Arg16Gly | Gly16Gly vs Arg16Arg/ Arg16Gly | ||||||||
| OR[95%CI] (p) | P-het | I2 | OR[95%CI] (p) | P-het | I2 | OR[95%CI] (p) | P-het | I2 | OR[95%CI] (p) | P-het | I2 | |||
| Overall | 29 | 5595/15184 | 1.06[1.01,1.12] | <0.00001 | 64% | 1.11[1.02,1.21] | 0.0007 | 52% | 0.94[0.87,1.02] 0.12 | 0.0006 | 52% | 1.10[0.99,1.22] 0.06 | <0.0001 | 58% |
| Ethnicity | ||||||||||||||
| Asian | 15 | 2882/2842 | 1.14[1.05,1.23] | <0.0001 | 67% | 1.26[1.12,1.43] | 0.008 | 53% | 0.91[0.81,1.04] 0.16 | 0.005 | 55% | 1.23[1.06,1.44] | 0.0002 | 66% |
| Caucasiann | 10 | 1726/10355 | 0.99[0.91,1.08] 0.89 | 0.002 | 65% | 0.94[0.80,1.10] 0.45 | 0.09 | 40% | 0.98[0.87,1.10] 0.72 | 0.003 | 64% | 0.98[0.82,1.17] 0.81 | 0.03 | 52% |
| Age | ||||||||||||||
| Children | 10 | 1817/3009 | 1.05[0.97,1.15] 0.23 | 0.0005 | 70% | 1.11[0.96,1.28] 0.15 | 0.005 | 62% | 0.96[0.84,1.10] 0.58 | 0.010 | 59% | 1.06[0.89,1.26] 0.52 | 0.002 | 66% |
| Adults | 17 | 3582/11925 | 1.04[0.98,1.11] 0.22 | 0.003 | 55% | 1.06[0.95,1.18] 0.32 | 0.08 | 35% | 0.95[0.86,1.05] 0.31 | 0.01 | 50% | 1.07[0.94,1.22] 0.32 | 0.02 | 47% |
n, number of studies.
Results of the pooled analyses and subgroup analyses for the β2AR Gln/Glu27 polymorphism and asthma risk.
| Variable | n | Case/Control | Gln27 vs Glu27 | Gln27Gln vs Glu27Glu | Gln27Gln vs Glu27Glu/ Gln27Glu | Glu27Glu vs Gln27Gln/ Gln27Glu | ||||||||
| OR[95%CI] (p) | P-het | I2 | OR[95%CI] (p) | P-het | I2 | OR[95%CI] (p) | P-het | I2 | OR[95%CI](p) | P-het | I2 | |||
| Overall | 22 | 3363/12337 | 1.07[0.99,1.15] 0.09 | 0.03 | 39% | 1.11[1.01,1.23] 0.03 | 0.005 | 49% | 1.02[0.89,1.18] 0.77 | 0.64 | 0% | 1.02[0.87,1.20] 0.80 | 0.89 | 0% |
| Overall# | 21 | 3060/11733 | 1.02[0.95,1.10] 0.59 | 0.50 | 0% | 1.03[0.93,1.14] 0.60 | 0.34 | 9% | 1.02[0.89,1.18] 0.74 | 0.58 | 0% | 1.01[0.86,1.20] 0.86 | 0.86 | 0% |
| Ethnicity | ||||||||||||||
| Asian | 9 | 1306/1286 | 1.10[0.91,1.32] 0.34 | 0.37 | 8% | 1.18[0.96,1.46] 0.18 | 0.32 | 14% | 0.72[0.42,1.23] 0.23 | 0.82 | 0% | 0.75[0.43,1.30] 0.31 | 0.93 | 0% |
| Caucasiann | 7 | 1367/9948 | 1.03[0.94,1.12] 0.58 | 0.20 | 30% | 1.02[0.89,1.17] 0.12 | 0.38 | 7% | 1.05[0.90,1.24] 0.51 | 0.10 | 44% | 1.06[0.88,1.28] 0.51 | 0.25 | 23% |
| Age | ||||||||||||||
| Children | 8 | 682/1104 | 0.96[0.81,1.13] 0.63 | 0.65 | 0% | 0.86[0.69,1.07] 0.18 | 0.79 | 0% | 1.21[0.86,1.73] 0.28 | 0.56 | 0% | 1.00[0.68,1.47] 0.99 | 0.76 | 0% |
| Adults | 12 | 2485/10987 | 1.10[1.01,1.19] | 0.007 | 57% | 1.20[1.07,1.34] 0.002 |
| 62% | 1.01[0.86,1.18] 0.93 | 0.57 | 0% | 1.05[0.88,1.26] 0.59 | 0.66 | 0% |
# Pooled result not included study of Santilan, A A#, n, number of studies.
Figure 2Galbraith plots of the association between β2AR Arg16Gly polymorphism and asthma.
A) Asian population subgroup; B) caucasian population subgroup. Four studies# maybe the main contributors to the heterogeneity Asian population subgroup; One studies# maybe the main contributors to the heterogeneity Asian population subgroup.
Figure 3Funnel plot of publication bias for β2AR polymorphism under recessive genetic model.
A) Arg/Gly16; B) Gln/Glu27. Funnel plot with pseudo 95% confidence limits was used.